CMPS COMPASS Pathways plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816590 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY14.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-296.5%
ROA-68.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets72.6%
Debt / equity0.36x
Current ratio1.50x
Interest coverage-35.36x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $118.44M | $119.04M | $87.52M | $65.05M | $44.03M |
| SG&A expense | $60.60M | $59.17M | $49.40M | $45.35M | $39.19M |
| Operating income | -$179.04M | -$178.21M | -$136.92M | -$110.40M | -$83.22M |
| Interest expense | $4.52M | $4.48M | $2.20M | $0 | $0 |
| Pretax income | -$290.33M | -$153.53M | -$117.68M | -$91.10M | -$71.54M |
| Income tax | -$2.47M | $1.59M | $780,000 | $408,000 | $199,000 |
| Net income | -$287.86M | -$155.12M | -$118.46M | -$91.50M | -$71.74M |
| EBITDA | -$178.82M | -$177.97M | -$136.68M | -$110.07M | -$83.05M |
| EPS (basic) | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 |
| EPS (diluted) | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 |
| Weighted avg. shares (diluted) | 93.50M | 67.48M | 51.03M | 42.44M | 40.00M |
| Balance sheet | |||||
| Cash & equivalents | $149.61M | $165.47M | $220.64M | $143.38M | $273.24M |
| Current assets | $191.49M | $201.29M | $261.30M | $191.65M | $295.30M |
| PP&E, net | — | $189,000 | $423,000 | $617,000 | $398,000 |
| Total assets | $210.35M | $213.67M | $275.99M | $197.29M | $300.90M |
| Current liabilities | $247.79M | $34.02M | $19.60M | $15.60M | $15.11M |
| Short-term debt | $17.52M | $5.51M | $0 | — | — |
| Long-term debt | $14.11M | $24.65M | $28.76M | $0 | — |
| Total debt | $31.63M | $30.16M | $28.76M | $0 | — |
| Total liabilities | $263.20M | $58.97M | $50.24M | $16.01M | $16.49M |
| Shareholders' equity | -$52.85M | $154.69M | $225.74M | $181.28M | $284.41M |
| Net debt | -$117.97M | -$135.31M | -$191.88M | -$143.38M | — |
| Shares outstanding | 96.09M | 68.55M | 61.94M | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$157.24M | -$119.19M | -$97.38M | -$105.45M | -$67.75M |
| Capital expenditure | — | $0 | $66,000 | $596,000 | $334,000 |
| Free cash flow | — | -$119.19M | -$97.44M | -$106.05M | -$68.08M |
| Investing cash flow | — | $0 | -$64,000 | -$596,000 | -$334,000 |
| Financing cash flow | $140.71M | $63.82M | $173.83M | $1.04M | $156.65M |
| Depreciation & amortization | $216,000 | $233,000 | $242,000 | $330,000 | $175,000 |
| Stock-based compensation | $13.59M | $19.52M | $17.28M | $13.12M | $8.64M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.